Related Experiment Videos
RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines
1National Institute for Cancer Research, Department of Clinical and Experimental Oncology, University of Genoa, Italy. Toma@sirio.cba.unige.it
Abstract:
Ro 41-5253 is a RARalpha-selective antagonist that binds RARalpha but does not induce transcriptional activation and does not influence RAR/RXR heterodimerization and DNA binding. This retinoid inhibits proliferation and induces apoptosis in MCF-7 and ZR-75.1 estrogen-receptor-positive breast-carcinoma cells in a dose-dependent way. The anti-proliferative effect is more evident in ZR-75.1 cells than in MCF-7 cells and is probably mediated by anti-AP1 activity, a mechanism known to be implied in the action of several retinoids. In the induction of apoptosis also ZR-75.1 cells are more sensitive to treatment with Ro 41-5253 than MCF-7 cells. In ZR-75.1 cells an apoptotic/hypodiploid DNA peak is already evident after 2 days of incubation, whereas in MCF-7 cells it appears only after 4 days. The highest percentage of apoptotic cells, for both cell lines, is reached after 6 days of treatment. The apoptosis pathway is p53-independent and bcl-2 downregulation seems to be correlated with an increase in TGF-beta1 protein. The MDA-MB-231 estrogen-receptor-negative cell line is poorly responsive to Ro 41-5253 treatment, both in terms of proliferation inhibition and apoptosis induction. Ro 41-5253 has proliferation-inhibiting and apoptosis-inducing properties that are not mediated by transcriptional activation from retinoic-acid response elements. This retinoid antagonist seems to be a compound that exerts an anti-tumor activity but does not induce the toxic side effects of retinoids and might, therefore, be considered as a candidate for cancer therapy.
Insights
Ro 41-5253, a retinoic acid receptor alpha (RARalpha)-selective antagonist, inhibits breast cancer cell proliferation and induces apoptosis. This compound shows potential for cancer therapy without typical retinoid side effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Retinoids modulate cell proliferation and differentiation.
- Retinoic acid receptors (RARs) are key mediators of retinoid action.
- RARalpha-selective antagonists offer targeted therapeutic potential.
Purpose of the Study:
- To investigate the effects of Ro 41-5253, a RARalpha-selective antagonist, on breast cancer cell lines.
- To determine the mechanisms underlying Ro 41-5253's anti-cancer activity.
- To evaluate the therapeutic potential of Ro 41-5253 in cancer treatment.
Main Methods:
- Treatment of MCF-7, ZR-75.1 (estrogen-receptor-positive), and MDA-MB-231 (estrogen-receptor-negative) breast cancer cells with Ro 41-5253.
- Assessment of cell proliferation, apoptosis induction, and DNA content.
- Analysis of p53, bcl-2, and TGF-beta1 expression.
- Evaluation of RAR/RXR heterodimerization and DNA binding.
Main Results:
- Ro 41-5253 inhibited proliferation and induced apoptosis in a dose-dependent manner in estrogen-receptor-positive breast cancer cells (MCF-7 and ZR-75.1).
- ZR-75.1 cells were more sensitive to Ro 41-5253 than MCF-7 cells regarding proliferation inhibition and apoptosis induction.
- Apoptosis was p53-independent and correlated with bcl-2 downregulation and increased TGF-beta1.
- Estrogen-receptor-negative MDA-MB-231 cells showed poor responsiveness to Ro 41-5253.
- Ro 41-5253's effects were not mediated by transcriptional activation from retinoic acid response elements.
Conclusions:
- Ro 41-5253 exhibits anti-tumor activity by inhibiting proliferation and inducing apoptosis in specific breast cancer subtypes.
- The compound's mechanism involves anti-AP1 activity and p53-independent apoptosis.
- Ro 41-5253 may offer a therapeutic advantage by avoiding the toxic side effects associated with traditional retinoids.
- Ro 41-5253 is a promising candidate for further investigation in cancer therapy.